Almac Discovery

Almac Discovery

Biotechnology Research

Craigavon, Non-US/Other 1,916 followers

Discovery to preclinical - seeking to license programmes early with a pharma partner for further development

About us

Passionate about oncology Almac Discovery enjoys the challenge of first-in-class and best-in-class projects (view our pipeline). The combination of the highest quality science and dedicated, passionate people position Almac Discovery as a partner of choice in the challenging world of modern drug discovery. We work creatively and energetically with all of our collaborators, industrial and academic, to translate early stage research from concept to therapeutic. Headquartered in Craigavon, Northern Ireland our research laboratories are based in the Centre for Precision Therapeutics in the heart of the life sciences and hospital campus at Queen’s University, Belfast. Our goal is to provide high quality oncology programmes in areas of unmet need and to develop those programmes with our partners and collaborators. We currently have active research in ubiquitin specific proteases and protein drug conjugates. Access to the extensive capabilities in pharmaceutical development available through our parent company, the Almac Group, enables us to engage in clinical stage oncology discovery and development . Currently, our lead programme, ALM201, is in clinical development. Within Almac Discovery we have developed a passionate and experienced team whose drive and commitment enables us to take forward highly innovative and challenging partnering opportunities.

Industry
Biotechnology Research
Company size
5,001-10,000 employees
Headquarters
Craigavon, Non-US/Other
Founded
2008
Specialties
ALM201: a very potent peptide anti-angiogenic with a novel mechanism of action., Novel allosteric inhibitors of Akt, including subtype-selective inhibitors., Nasal granisetron for the treatment of CINV., and Targeted leukapheresis for the treatment of IBD.

Updates

Affiliated pages

Similar pages